AAAAAA

   
Results: 1-25 | 26-50 | 51-55
Results: 26-50/55
EFFECT OF N-0861, A SELECTIVE ADENOSINE-A1-RECEPTOR ANTAGONIST, ON PHARMACOLOGICAL STRESS IMAGING WITH ADENOSINE
Authors: GLOVER DK RUIZ M SANSOY V BARRETT RJ BELLER GA
Citation: Dk. Glover et al., EFFECT OF N-0861, A SELECTIVE ADENOSINE-A1-RECEPTOR ANTAGONIST, ON PHARMACOLOGICAL STRESS IMAGING WITH ADENOSINE, The Journal of nuclear medicine, 36(2), 1995, pp. 270-275
D-2-SPECIFIC DISCRIMINATIVE STIMULI - PARAMETERS, BLOCKING, AND REBOUND
Authors: HUFFMAN EM CAUL WF STRAND EJ JONES JR BARRETT RJ
Citation: Em. Huffman et al., D-2-SPECIFIC DISCRIMINATIVE STIMULI - PARAMETERS, BLOCKING, AND REBOUND, Pharmacology, biochemistry and behavior, 51(1), 1995, pp. 77-82
RACIAL-DIFFERENCES IN TUMOR GRADE AMONG WOMEN WITH ENDOMETRIAL CANCER
Authors: HILL HA COATES RJ AUSTIN H CORREA P ROBBOY SJ CHEN V CLICK LA BARRETT RJ BOYCE JG KOTZ HL HARLAN LC
Citation: Ha. Hill et al., RACIAL-DIFFERENCES IN TUMOR GRADE AMONG WOMEN WITH ENDOMETRIAL CANCER, Gynecologic oncology, 56(2), 1995, pp. 154-163
NEUROCHEMICAL AND BEHAVIORAL EVIDENCE THAT QUIPAZINE-KETANSERIN DISCRIMINATION IS MEDIATED BY SEROTONIN(2A) RECEPTOR
Authors: SMITH RL BARRETT RJ SANDERSBUSH E BARRETT RS
Citation: Rl. Smith et al., NEUROCHEMICAL AND BEHAVIORAL EVIDENCE THAT QUIPAZINE-KETANSERIN DISCRIMINATION IS MEDIATED BY SEROTONIN(2A) RECEPTOR, The Journal of pharmacology and experimental therapeutics, 275(2), 1995, pp. 1050-1057
ENDOMETRIAL CANCER - STAGE AT DIAGNOSIS AND ASSOCIATED FACTORS IN BLACK-AND-WHITE PATIENTS
Authors: BARRETT RJ HARLAN LC WESLEY MN HILL HA CHEN VW CLAYTON LA KOTZ HL ELEY W ROBBOY SJ EDWARDS BK
Citation: Rj. Barrett et al., ENDOMETRIAL CANCER - STAGE AT DIAGNOSIS AND ASSOCIATED FACTORS IN BLACK-AND-WHITE PATIENTS, American journal of obstetrics and gynecology, 173(2), 1995, pp. 414-423
DRUG DISCRIMINATION IS A CONTINUOUS RATHER THAN A QUANTAL PROCESS FOLLOWING TRAINING ON A VI-TO SCHEDULE OF REINFORCEMENT
Authors: BARRETT RJ CAUL WF HUFFMAN EM SMITH RL
Citation: Rj. Barrett et al., DRUG DISCRIMINATION IS A CONTINUOUS RATHER THAN A QUANTAL PROCESS FOLLOWING TRAINING ON A VI-TO SCHEDULE OF REINFORCEMENT, Psychopharmacology, 113(3-4), 1994, pp. 289-296
CONTINUOUS OR QUANTAL DATA IN DRUG DISCRIMINATION EXPERIMENTS IS A MEASUREMENT ISSUE NOT A REINFORCEMENT ISSUE - DISADVANTAGES OF QUANTAL DRUG DISCRIMINATION PROCEDURES - DRUG DISCRIMINATION IS A CONTINUOUS RATHER THAN A QUANTAL PROCESS FOLLOWING TRAINING ON A VI-TO SCHEDULE OF REINFORCEMENT - REPLY
Authors: BARRETT RJ CAUL WF HUFFMAN EM SMITH RL
Citation: Rj. Barrett et al., CONTINUOUS OR QUANTAL DATA IN DRUG DISCRIMINATION EXPERIMENTS IS A MEASUREMENT ISSUE NOT A REINFORCEMENT ISSUE - DISADVANTAGES OF QUANTAL DRUG DISCRIMINATION PROCEDURES - DRUG DISCRIMINATION IS A CONTINUOUS RATHER THAN A QUANTAL PROCESS FOLLOWING TRAINING ON A VI-TO SCHEDULE OF REINFORCEMENT - REPLY, Psychopharmacology, 113(3-4), 1994, pp. 302-303
ENDOMETRIAL CANCER RISK IN RELATION TO SERUM-LIPIDS AND LIPOPROTEIN LEVELS
Authors: SWANSON CA POTISCHMAN N BARRETT RJ BERMAN ML MORTEL R TWIGGS LB WILBANKS GD HOOVER RN BRINTON LA
Citation: Ca. Swanson et al., ENDOMETRIAL CANCER RISK IN RELATION TO SERUM-LIPIDS AND LIPOPROTEIN LEVELS, Cancer epidemiology, biomarkers & prevention, 3(7), 1994, pp. 575-581
WRC-470 (2-CYCLOHEXYLMETHYLHYDRAZINOADENOSINE) - A NEW SELECTIVE ADENOSINE-A(2A) RECEPTOR AGONIST WITH POTENTIAL FOR PHARMACOLOGICAL STRESSIMAGING
Authors: GLOVER DK RUIZ M KOPLAN BA ALLEN TR KRYZHANOVSKI V SMITH W WATSON DD BARRETT RJ BELLER GA
Citation: Dk. Glover et al., WRC-470 (2-CYCLOHEXYLMETHYLHYDRAZINOADENOSINE) - A NEW SELECTIVE ADENOSINE-A(2A) RECEPTOR AGONIST WITH POTENTIAL FOR PHARMACOLOGICAL STRESSIMAGING, Journal of the American College of Cardiology, 1994, pp. 10000127-10000127
PHASE-II TRIAL OF PACLITAXEL IN PATIENTS WITH PROGRESSIVE OVARIAN-CARCINOMA AFTER PLATINUM-BASED CHEMOTHERAPY - A GYNECOLOGIC-ONCOLOGY-GROUP STUDY
Authors: THIGPEN JT BLESSING JA BALL H HUMMEL SJ BARRETT RJ
Citation: Jt. Thigpen et al., PHASE-II TRIAL OF PACLITAXEL IN PATIENTS WITH PROGRESSIVE OVARIAN-CARCINOMA AFTER PLATINUM-BASED CHEMOTHERAPY - A GYNECOLOGIC-ONCOLOGY-GROUP STUDY, Journal of clinical oncology, 12(9), 1994, pp. 1748-1753
HOT AND COLD IN TRANSFORMATION - IS IBAN MEDICINE HUMORAL
Authors: BARRETT RJ LUCAS RH
Citation: Rj. Barrett et Rh. Lucas, HOT AND COLD IN TRANSFORMATION - IS IBAN MEDICINE HUMORAL, Social science & medicine, 38(2), 1994, pp. 383-393
RENAL HEMODYNAMIC AND EXCRETORY EFFECTS OF N-0861, A NONXANTHINE ADENOSINE A(1)-RECEPTOR ANTAGONIST
Authors: BARRETT RJ WRIGHT KF DROPPLEMAN DA
Citation: Rj. Barrett et al., RENAL HEMODYNAMIC AND EXCRETORY EFFECTS OF N-0861, A NONXANTHINE ADENOSINE A(1)-RECEPTOR ANTAGONIST, Drug development research, 32(3), 1994, pp. 196-203
PHASE-II TRIAL OF MENOGARIL IN PATIENTS WITH SQUAMOUS CARCINOMA OF THE CERVIX - A GYNECOLOGIC-ONCOLOGY-GROUP STUDY
Authors: SUTTON GP BLESSING JA BARRETT RJ GALLUP DG
Citation: Gp. Sutton et al., PHASE-II TRIAL OF MENOGARIL IN PATIENTS WITH SQUAMOUS CARCINOMA OF THE CERVIX - A GYNECOLOGIC-ONCOLOGY-GROUP STUDY, Gynecologic oncology, 52(2), 1994, pp. 229-231
DISCRIMINATION OF A(1) VERSES A(2) RECEPTOR SUBTYPE SELECTIVITY OF ADENOSINE RECEPTOR AGONISTS IN-VIVO
Authors: BARRETT RJ DROPPLEMAN DA WRIGHT KF
Citation: Rj. Barrett et al., DISCRIMINATION OF A(1) VERSES A(2) RECEPTOR SUBTYPE SELECTIVITY OF ADENOSINE RECEPTOR AGONISTS IN-VIVO, The Journal of pharmacology and experimental therapeutics, 268(3), 1994, pp. 1166-1173
A SELECTIVE ADENOSINE A(1) RECEPTOR ANTAGONIST ATTENUATES RENAL DYSFUNCTION DURING CONTROLLED HYPOTENSION WITH ADENOSINE IN RATS
Authors: BARRETT RJ WRIGHT KF
Citation: Rj. Barrett et Kf. Wright, A SELECTIVE ADENOSINE A(1) RECEPTOR ANTAGONIST ATTENUATES RENAL DYSFUNCTION DURING CONTROLLED HYPOTENSION WITH ADENOSINE IN RATS, Anesthesia and analgesia, 79(3), 1994, pp. 460-465
RELATION OF ENDOMETRIAL CANCER RISK TO PAST AND CONTEMPORARY BODY-SIZE AND BODY-FAT DISTRIBUTION
Authors: SWANSON CA POTISCHMAN N WILBANKS GD TWIGGS LB MORTEL R BERMAN ML BARRETT RJ BAUMGARTNER RN BRINTON LA
Citation: Ca. Swanson et al., RELATION OF ENDOMETRIAL CANCER RISK TO PAST AND CONTEMPORARY BODY-SIZE AND BODY-FAT DISTRIBUTION, Cancer epidemiology, biomarkers & prevention, 2(4), 1993, pp. 321-327
MODERATE ALCOHOL-CONSUMPTION AND THE RISK OF ENDOMETRIAL CANCER
Authors: SWANSON CA WILBANKS GD TWIGGS LB MORTEL R BERMAN ML BARRETT RJ BRINTON LA
Citation: Ca. Swanson et al., MODERATE ALCOHOL-CONSUMPTION AND THE RISK OF ENDOMETRIAL CANCER, Epidemiology, 4(6), 1993, pp. 530-536
DIETARY ASSOCIATIONS IN A CASE-CONTROL STUDY OF ENDOMETRIAL CANCER
Authors: POTISCHMAN N SWANSON CA BRINTON LA MCADAMS M BARRETT RJ BERMAN ML MORTEL R TWIGGS LB WILBANKS GD HOOVER RN
Citation: N. Potischman et al., DIETARY ASSOCIATIONS IN A CASE-CONTROL STUDY OF ENDOMETRIAL CANCER, CCC. Cancer causes & control, 4(3), 1993, pp. 239-250
CIRCADIAN-TIMED COMBINATION DOXORUBICIN-CISPLATIN CHEMOTHERAPY FOR ADVANCED ENDOMETRIAL CARCINOMA - A PHASE-II STUDY OF THE GYNECOLOGIC-ONCOLOGY-GROUP
Authors: BARRETT RJ BLESSING JA HOMESLEY HD TWIGGS L WEBSTER KD
Citation: Rj. Barrett et al., CIRCADIAN-TIMED COMBINATION DOXORUBICIN-CISPLATIN CHEMOTHERAPY FOR ADVANCED ENDOMETRIAL CARCINOMA - A PHASE-II STUDY OF THE GYNECOLOGIC-ONCOLOGY-GROUP, American journal of clinical oncology, 16(6), 1993, pp. 494-496
A PHASE-II TRIAL OF TRICYCLIC NUCLEOSIDE PHOSPHATE IN PATIENTS WITH ADVANCED SQUAMOUS-CELL CARCINOMA OF THE CERVIX - A GYNECOLOGIC-ONCOLOGY-GROUP STUDY
Authors: FEUN LG BLESSING JA BARRETT RJ HANJANI P
Citation: Lg. Feun et al., A PHASE-II TRIAL OF TRICYCLIC NUCLEOSIDE PHOSPHATE IN PATIENTS WITH ADVANCED SQUAMOUS-CELL CARCINOMA OF THE CERVIX - A GYNECOLOGIC-ONCOLOGY-GROUP STUDY, American journal of clinical oncology, 16(6), 1993, pp. 506-508
TOPICAL SUCRALFATE IN THE TREATMENT OF VAGINAL ULCERATION
Authors: LENTZ SS BARRETT RJ HOMESLEY HD
Citation: Ss. Lentz et al., TOPICAL SUCRALFATE IN THE TREATMENT OF VAGINAL ULCERATION, Obstetrics and gynecology, 81(5), 1993, pp. 869-871
THE SKULLS ARE COLD, THE HOUSE IS HOT - INTERPRETING DEPTHS OF MEANING IN IBAN THERAPY
Authors: BARRETT RJ LUCAS RH
Citation: Rj. Barrett et Rh. Lucas, THE SKULLS ARE COLD, THE HOUSE IS HOT - INTERPRETING DEPTHS OF MEANING IN IBAN THERAPY, Man, 28(3), 1993, pp. 573-596
INVITRO AND INVIVO PHARMACOLOGICAL CHARACTERIZATION OF N6-CYCLOPENTYL-9-METHYLADENINE(N-0840) - A SELECTIVE, ORALLY ACTIVE A1 ADENOSINE RECEPTOR ANTAGONIST
Authors: BARRETT RJ MAY JM MARTIN PL MILLER JR
Citation: Rj. Barrett et al., INVITRO AND INVIVO PHARMACOLOGICAL CHARACTERIZATION OF N6-CYCLOPENTYL-9-METHYLADENINE(N-0840) - A SELECTIVE, ORALLY ACTIVE A1 ADENOSINE RECEPTOR ANTAGONIST, The Journal of pharmacology and experimental therapeutics, 265(1), 1993, pp. 227-236
ORAL-CONTRACEPTIVES AND ENDOMETRIAL CANCER - DO OTHER RISK-FACTORS MODIFY THE ASSOCIATION
Authors: STANFORD JL BRINTON LA BERMAN ML MORTEL R TWIGGS LB BARRETT RJ WILBANKS GD HOOVER RN
Citation: Jl. Stanford et al., ORAL-CONTRACEPTIVES AND ENDOMETRIAL CANCER - DO OTHER RISK-FACTORS MODIFY THE ASSOCIATION, International journal of cancer, 54(2), 1993, pp. 243-248
DOES N-0861 (A NEW ADENOSINE-A1-RECEPTOR ANTAGONIST) AFFECT THE ASSESSMENT OF CORONARY FLOW RESERVE USING TL-201 IMAGING
Authors: GLOVER DK RUIZ M SANSOY V BARRETT RJ BELLER GA
Citation: Dk. Glover et al., DOES N-0861 (A NEW ADENOSINE-A1-RECEPTOR ANTAGONIST) AFFECT THE ASSESSMENT OF CORONARY FLOW RESERVE USING TL-201 IMAGING, Circulation, 88(4), 1993, pp. 439-439
Risultati: 1-25 | 26-50 | 51-55